SCHEMBL25848927

SCHEMBL25848927

CNS(=O)(=O)c1ccc(C(=O)NCc2ccc(Cl)c(F)c2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.40
F10 P00742 1/20 0.40
MAPK1 P28482 1/20 0.40
CHRM4 P08173 2/20 0.39
SCN3A Q9NY46 1/20 0.39
CNR2 P34972 1/20 0.39
HPGD P15428 1/20 0.39
PPARG P37231 1/20 0.39
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AKT3 Q9Y243 1/20 0.38
TSHR P16473 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848781 0.88 KMT2A (0.41) KDM4ELMNAKMT2ACHRM4NPC1
SCHEMBL25848884 0.83 CCR1 (0.47) KDM4ELMNAKMT2ACHRM4HPGD
SCHEMBL25261026 0.82 DYRK1A (0.50) KMT2AF10NPC1AKT3MAOB
SCHEMBL30393532 0.82 DYRK1A (0.50) KMT2AF10NPC1AKT3MAOB
SCHEMBL25848887 0.80 EPHX2 (0.45) MAPK1HDAC1HDAC6
SCHEMBL25848775 0.80 MEN1 (0.52) KDM4ELMNAKMT2AHPGDALDH1A1
SCHEMBL25848782 0.79 KMT2A (0.49) KDM4EKMT2ANPC1ALDH1A1RAB9A
SCHEMBL25848928 0.79 CA1 (0.46) KDM4EKMT2ACHRM4SMN1; SMN2AKT3
SCHEMBL25848785 0.78 MMP13 (0.49) KDM4ELMNAKMT2AF10HPGD
SCHEMBL25849324 0.78 PPARA (0.49) CHRM4SCN3APPARGHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
EP-4175624-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2023-05-10 EP disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 KDM4E 1355/4885LMNA 1423/4885KMT2A 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.